SNPMiner Trials by Shray Alag


SNPMiner Trials: Clinical Trial Report


Report for Clinical Trial NCT03778229

Developed by Shray Alag, 2019.
SNP Clinical Trial Gene

A Phase II, Single Arm Study Assessing Efficacy of Osimertinib With Savolitinib in Patients With EGFRm+ MET+, Locally Advanced or Metastatic Non Small Cell Lung Cancer Who Have Progressed Following Osimertinib Treatment (SAVANNAH Study)

This study (the SAVANNAH study) will investigate the efficacy of osimertinib in combination with savolitinib in patients with EGFRm+ and MET+, locally advanced or metastatic NSCLC who have progressed following treatment with osimertinib.

NCT03778229 Carcinoma

2 Interventions

Name: osimertinib

Description: osimertinib (80 mg oral od).

Type: Drug

osimertinib + savolitinib

Name: savolitinib

Description: savolitinib (300 mg oral OD or 600 mg oral OD)

Type: Drug

osimertinib + savolitinib


Primary Outcomes

Description: To determine the efficacy of savolitinib in combination with osimertinib in patients with EGFRm+, MET+ (determined centrally by FISH), locally advanced or metastatic NSCLC who have progressed on osimertinib. The primary analysis of ORR will occur when all patients have had the opportunity to be treated for 6 months.

Measure: Objective response rate (ORR) by investigator assessment in accordance with RECIST 1.1

Time: Up to approximately 36 months after 1st patient dosed (117 centrally confirmed MET+ FISH patients).

Secondary Outcomes

Description: To determine the efficacy of savolitinib in combination with osimertinib in patients with EGFRm+, MET+ (centrally confirmed by IHC and in all patients) locally advanced or metastatic NSCLC who have progressed on osimertinib.

Measure: Objective response rate (ORR) by investigator assessment in accordance with RECIST 1.1.

Time: Up to approximately 36 months after 1st patient dosed (at the time of the primary outcome measure assessment).

Description: To determine the efficacy of savolitinib in combination with osimertinib in patients with EGFRm+, MET+, locally advanced or metastatic NSCLC who have progressed on osimertinib. In patients centrally confirmed as MET positive by FISH, by IHC and in all patients.

Measure: PFS by investigator assessment in accordance with RECIST 1.1.

Time: Up to approximately 36 months after 1st patient dosed (at the time of the primary outcome measure assessment).

Description: To assess the impact of savolitinib and osimertinib on disease related symptoms and health related quality of life (HRQoL) in patients centrally confirmed as MET positive by FISH, by IHC and in all patients.

Measure: Mean change from baseline in the European Organisation for Research and Treatment of Cancer (EORTC) 30-item core quality-of-life questionnaire (QLQ-C30), version 3 (QLQ-C30 v3).

Time: Up to approximately 36 months after 1st patient dosed (at the time of the primary outcome measure assessment).

Description: To evaluate the pharmacokinetics of osimertinib and savolitinib in this patient population.

Measure: Plasma concentrations of osimertinib, savolitinib and their metabolites.

Time: Blood sampling on Cycles 1 and 2 on Day 1 pre-dose, 1 hour and 3 hours post-dose; Day 1 of Cycles 3, 6, and 11; discontinuation visit (if discontinued due to liver toxicity) (One cycle = 28 days)

Description: To determine the rate of ctDNA clearance after osimertinib and savolitinib treatment in patients centrally confirmed as MET positive by FISH, by IHC and in all patients.

Measure: Total clearance in EGFR mutations at 6-weeks after therapy initiation (percentage and absolute change from baseline in EGFR mutation allele frequencies).

Time: From date of first dose until the date of first documented progression, up to approximately 36 months.

Description: To evaluate the safety and tolerability of savolitinib in combination with osimertinib.

Measure: AEs, SAEs and discontinuation rate due to AEs, as characterized and graded by National Cancer Institute (NCI) Common Terminology Criteria for Adverse Event [CTCAE] v5.

Time: Continuously from first dose to 28 (+/-7) days after discontinuation of study drug, or up to approximately 36 months.

Description: To determine the efficacy of savolitinib in combination with osimertinib in patients with EGFRm+, MET+, locally advanced or metastatic NSCLC who have progressed on osimertinib. In patients centrally confirmed as MET positive by FISH, by IHC and in all patients.

Measure: Overall Survival by investigator assessment in accordance with RECIST 1.1.

Time: Up to approximately 36 months after 1st patient dosed (at the time of the primary outcome measure assessment).

Description: To determine the efficacy of savolitinib in combination with osimertinib in patients with EGFRm+, MET+, locally advanced or metastatic NSCLC who have progressed on osimertinib. In patients centrally confirmed as MET positive by FISH, by IHC and in all patients.

Measure: Duration of Response by investigator assessment in accordance with RECIST 1.1.

Time: Up to approximately 36 months after 1st patient dosed (at the time of the primary outcome measure assessment).

Description: To determine the efficacy of savolitinib in combination with osimertinib in patients with EGFRm+, MET+, locally advanced or metastatic NSCLC who have progressed on osimertinib. In patients centrally confirmed as MET positive by FISH, by IHC and in all patients.

Measure: Percentage change in tumour size by investigator assessment in accordance with RECIST 1.1.

Time: Up to approximately 36 months after 1st patient dosed (at the time of the primary outcome measure assessment).

Description: To assess the impact of savolitinib and osimertinib on disease related symptoms and health related quality of life (HRQoL) in patients centrally confirmed as MET positive by FISH, by IHC and in all patients.

Measure: Mean change from baseline in the European Organisation for Research and Treatment of Cancer (EORTC) complementary 13-item quality-of-life questionnaire - lung cancer symptoms questionnaire (QLQ-LC13).

Time: Up to approximately 36 months after 1st patient dosed (at the time of the primary outcome measure assessment).

Other Outcomes

Description: To assess the impact of savolitinib in combination with osimertinib on patient reported treatment-related symptoms.

Measure: PRO CTCAE symptoms

Time: From date of consent until the date of first documented progression, up to approximately 36 months.

Description: To assess patients' overall impression of severity of cancer symptoms. In patients centrally confirmed as MET positive by FISH, by IHC and in all patients.

Measure: Patient's Global Impression of Severity (PGIS)

Time: From date of consent until the date of first documented progression, up to approximately 36 months.

Description: To explore the impact of treatment and disease on health state utility. In patients centrally confirmed as MET positive by FISH, by IHC and in all patients.

Measure: EQ-5D-5L

Time: From date of consent until the date of first documented progression, up to approximately 36 months.

Description: To assess the predictive value of changes in circulating biomarkers on clinical efficacy endpoints.

Measure: Longitudinal changes in circulating DNA and/or RNA compared with PFS, OS and ORR.

Time: Blood samples collected at Screening within 28 days before the first dose of study treatment; on day of first dose of study treatment; at discontinuation 7 days after last dose of study treatment. (One cycle = 28 days)

Description: To collect and store DNA (according to each country's local and ethical procedures) for future exploratory research into genes/genetic variation that may influence response (ie, distribution, safety, tolerability and efficacy) to study treatments and or susceptibility to disease (optional).

Measure: Pharmacogenetic analyses on blood samples.

Time: Screening within 28 days before first dose; at first dose; 7 days after last dose. (One cycle = 28 days)

Description: To collect and store tissue and plasma samples for companion diagnostic development and exploratory analyses.

Measure: Disease relevant or response markers in tumour tissue and circulating tumour DNA/RNA including but not limited to EGFR mutations and MET amplifications.

Time: Screening within 28 days before first dose; at first dose; 7 days after last dose. Tumour tissue collected during Pre-screening and at treatment discontinuation 7 days after last dose. (One cycle = 28 days)

Description: To collect and store germline DNA for exploration of the role of HLA alleles in developmental toxicity.

Measure: HLA alleles associated with susceptibility to drug related AEs (such as but not limited to hypersensitivity).

Time: On first day of study treatment at Cycle 1 Day 1. (One cycle = 28 days)

Purpose: Treatment

Single Group Assignment


There is one SNP

SNPs


1 L858R

- Histologically or cytologically confirmed locally advanced or metastatic EGFRm+ NSCLC harbouring an EGFR mutation known to be associated with EGFR TKI sensitivity (including either exon 19 deletion and/or L858R) which is not amenable to curative therapy. --- L858R ---



HPO Nodes